A new peanut allergy treatment could keep a promise for children who are otherwise suffering serious reactions.

An experimental drug that shows that it is possible to build peanut tolerance over time is ready to review the US government and drugs. Final research results published in The New Zealand Medical Journal was also presented at the annual scientific conference of the American College of Allergy, Asthma and Immunology on Sunday.

The third phase of the study included 551 people, most of them aged 4 to 17, with a history of reactions that jeopardized life after peanut consumption. For several months, the participants received an experimental drug produced by peanuts daily.

The authors of the study hoped that the treatment would allow patients one or two peanuts a day without a severe reaction. The allergist and co-author Stephen Tilles said he was pleased to find that two thirds of the people in the study can tolerate two peanuts daily after nine to 12 months of treatment – half can eat four peanuts a day. Almost all children have experienced allergic reactions during a one-year trial funded by Aimmune Therapeutics, but less than five percent are classified as serious.

"We are excited about the potential to help children and adolescents protect pean allergy from accidental foods with peanuts in it," he said in a statement.

There are currently no approved treatments for those who suffer from peanut allergies.

Co-author and allergist Jai Lieberman, vice president of the ACAAI Food Allergy Committee, expects the drug to be approved for use at the end of next year.

"This is not a quick fix, and that does not mean people with [a] Peanut allergy will be able to eat peanuts whenever they want, "Liberman said in a statement." But it's definitely a breakthrough. "

Follow Ashlei Mai on Twitter: @ AshleiMaiTweets

Read or share this story: https: //vvv.usatodai.com/stori/nevs/health/2018/11/19/peanut-allergi-drug-medicine-readi-fda-reviev-offers-hope/2052833002/